Paper · 40208185
Comprehensive Analysis of GPSM2: From Pan-Cancer Analysis to Experimental Validation.
Yang C and 6 others. J Cell Mol Med, 2025. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comprehensive Analysis of GPSM2: From Pan-Cancer Analysis to Experimental Validation. Papers, record 40208185. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40208185
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Humans | |
| Gene Expression Regulation, Neoplastic | |
| Biomarkers, Tumor | |
| Prognosis | |
| Cell Line, Tumor | |
| Gene Expression Profiling |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022-MS-196 | Natural Science Foundation of Liaoning Province | PubMed | ||
| RC200267 | Shenyang Youth Science and Technology Innovation Talent Project | PubMed | ||
| 82073244 | National Natural Science Foundation of China | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29,463,900 | Modifications and functional genomics of human transfer RNA. | Cell Res | 2018 | https://conductscience.org/library/papers/29463900 | PubMed |
| 2 | 38,773,440 | Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38773440 | PubMed |
| 3 | 31,940,268 | Top 10 Challenges in Cancer Immunotherapy. | Immunity | 2020 | https://conductscience.org/library/papers/31940268 | PubMed |
| 4 | 35,690,784 | Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35690784 | PubMed |
| 5 | 30,996,127 | Cancer stemness, intratumoral heterogeneity, and immune response across cancers. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/30996127 | PubMed |
| 6 | 38,042,769 | A pan-cancer analysis indicates long noncoding RNA HAND2-AS1 as a potential prognostic, immunomodulatory and therapeutic biomarker in various cancers including colorectal adenocarcinoma. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/38042769 | PubMed |
| 7 | 31,731,749 | Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31731749 | PubMed |
| 8 | 18,316,549 | Therapeutic nanoparticles for drug delivery in cancer. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18316549 | PubMed |
| 9 | 23,537,665 | Synergistic gene and drug tumor therapy using a chimeric peptide. | Biomaterials | 2013 | https://conductscience.org/library/papers/23537665 | PubMed |
| 10 | 35,680,424 | Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. | Genes Dev | 2022 | https://conductscience.org/library/papers/35680424 | PubMed |
1 to 10 of 42
See all 42 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,724,844 | Microplastics and nanoplastics-related genes signature predicts prognosis in pancreatic ductal adenocarcinoma and functional validation of interleukin 1 alpha. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724844 | PubMed |
| 42,231,052 | GPSM2 Promotes Pancreatic Cancer Progression Through METTL3-Mediated m6A Modification of YAP1 mRNA. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42231052 | PubMed |
| 41,311,809 | Discovery of PAK2 as a Key Regulator of Cancer Stem Cell in Head and Neck Squamous Cell Carcinoma Using Multi-Omic Techniques. | Stem Cells Int | 2025 | https://conductscience.org/library/papers/41311809 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GPSM2 | 29,899 | PubTator's text mining | https://conductscience.org/library/genes/29899 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40208185
GET https://conductscience.org/api/papers/v1/40208185/references?page=2